Japan’s top drug maker, Takeda Pharmaceutical, said it aims to release a successor to its blockbuster anti-ulcer drug Prevacid in 2008, before the drug’s patent expires in 2009, president Yasuchika Hasegawa told Reuters yesterday.
Hasegawa said the drug, which has not been disclosed in the company’s pipeline list, is a 50-50 joint venture with Abbott Laboratories.
Hasegawa said further details about the product would be unveiled soon.
Prevacid is Takeda’s top-seller with global sales topping $3.4 billion in 2004/2005.
The drug is marketed in the U.S. by TAP Pharmaceuticals, also joint venture between Takeda and Abbott.
Takeda to release Prevacid follow-up in 2008
Japan’s top drug maker, Takeda Pharmaceutical, said it aims to release a successor to its blockbuster anti-ulcer drug Prevacid in 2008, before the drug’s patent expires in 2009, president Yasuchika Hasegawa told Reuters yesterday.
